Transient HPV is the norm, whereas persistent high-risk HPV over years drives cervical dysplasia and malignant transformation, supporting longitudinal surveillance when high-risk types are identified.
In May 2024, the Food and Drug Administration (FDA) approved two new cervical screening tests for detecting human papillomavirus (HPV), which causes almost all cervical cancers. Both allow individuals ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results